ADVERSE REACTIONS
Adverse events occurring in approximately 10-20% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse events occurring in approximately 5-9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
Adverse events occurring in approximately 1-4% of the subjects receiving brimonidine ophthalmic solution (0.1-0.2%) included: allergic reaction, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection (primarily colds and respiratory infections), insomnia, keratitis, lid disorder, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.
The following events were reported in less than 1% of subjects: corneal erosion, hordeolum, nasal dryness, and taste perversion.
The following events have been identified during post-marketing use of brimonidine tartrate ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, or a combination of these factors, include: bradycardia; depression; iritis; keratoconjunctivitis sicca; miosis; nausea; skin reactions (including erythema, eyelid pruritus, rash, and vasodilation) and tachycardia. Apnea; bradycardia; hypotension; hypothermia; hypotonia; and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions.
|
REPORTS OF SIDE EFFECTS / ADVERSE REACTIONS RELATED TO ALPHAGAN P
Below is a sample of reports where side effects / adverse reactions may be related to Alphagan P. The information is not vetted and should not be cosidered as verified clinical evidence.
Possible Alphagan P side effects / adverse reactions in 26 year old female
Reported by a physician from Korea, Republic of on 2007-02-06
Patient: 26 year old female
Reactions: Drug Ineffective, Intraocular Pressure Increased, Vision Blurred, Visual Acuity Reduced, Corneal Oedema
Adverse event resulted in: hospitalization
Suspect drug(s):
Cosopt
Dosage: opht
Indication: Developmental Glaucoma
Cosopt
Dosage: opht
Indication: Open Angle Glaucoma
Alphagan P
Dosage: opht
Indication: Developmental Glaucoma
Alphagan P
Dosage: opht
Indication: Open Angle Glaucoma
Xalatan
Dosage: opht
Indication: Developmental Glaucoma
Xalatan
Dosage: opht
Indication: Open Angle Glaucoma
Possible Alphagan P side effects / adverse reactions in 85 year old female
Reported by a physician from United States on 2007-02-07
Patient: 85 year old female
Reactions: Death
Adverse event resulted in: death
Suspect drug(s):
Alphagan P
Dosage: unk, bid
Indication: Glaucoma
Start date: 2006-10-06
End date: 2007-01-22
Lumigan
Indication: Glaucoma
Start date: 2006-10-06
End date: 2007-01-22
Possible Alphagan P side effects / adverse reactions in 26 year old female
Reported by a physician from Korea, Republic of on 2007-02-14
Patient: 26 year old female
Reactions: Drug Ineffective, Intraocular Pressure Increased, Vision Blurred, Retinal Disorder, Optic Nerve Cup/disc Ratio Increased, Condition Aggravated, Visual Acuity Reduced, Corneal Oedema
Adverse event resulted in: hospitalization
Suspect drug(s):
Cosopt
Dosage: unk opht
Indication: Developmental Glaucoma
Cosopt
Dosage: unk opht
Indication: Open Angle Glaucoma
Alphagan P
Dosage: unk opht
Indication: Developmental Glaucoma
Alphagan P
Dosage: unk opht
Indication: Open Angle Glaucoma
Xalatan
Dosage: unk opht
Indication: Developmental Glaucoma
Xalatan
Dosage: unk opht
Indication: Open Angle Glaucoma
|
